- Home
- NVAX vs LILAK Comparison
NVAX vs LILAK Comparison
Compare NVAX & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- LILAK
- Stock Information
- Founded
- NVAX 1987
- LILAK 2017
- Country
- NVAX United States
- LILAK Bermuda
- Employees
- NVAX N/A
- LILAK N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- LILAK Cable & Other Pay Television Services
- Sector
- NVAX Health Care
- LILAK Telecommunications
- Exchange
- NVAX Nasdaq
- LILAK Nasdaq
- Market Cap
- NVAX 1.3B
- LILAK 1.1B
- IPO Year
- NVAX 1995
- LILAK N/A
- Fundamental
- Price
- NVAX $6.80
- LILAK $6.60
- Analyst Decision
- NVAX Buy
- LILAK Buy
- Analyst Count
- NVAX 5
- LILAK 3
- Target Price
- NVAX $16.60
- LILAK $10.27
- AVG Volume (30 Days)
- NVAX 5.2M
- LILAK 1.1M
- Earning Date
- NVAX 08-07-2025
- LILAK 08-05-2025
- Dividend Yield
- NVAX N/A
- LILAK N/A
- EPS Growth
- NVAX N/A
- LILAK N/A
- EPS
- NVAX 2.97
- LILAK N/A
- Revenue
- NVAX $1,254,962,000.00
- LILAK $4,441,000,000.00
- Revenue This Year
- NVAX $56.85
- LILAK $2.45
- Revenue Next Year
- NVAX N/A
- LILAK $3.11
- P/E Ratio
- NVAX $2.29
- LILAK N/A
- Revenue Growth
- NVAX 25.92
- LILAK N/A
- 52 Week Low
- NVAX $5.01
- LILAK $4.23
- 52 Week High
- NVAX $17.81
- LILAK $10.93
- Technical
- Relative Strength Index (RSI)
- NVAX 51.68
- LILAK 74.11
- Support Level
- NVAX $6.23
- LILAK $5.78
- Resistance Level
- NVAX $6.90
- LILAK $6.53
- Average True Range (ATR)
- NVAX 0.30
- LILAK 0.24
- MACD
- NVAX 0.01
- LILAK 0.09
- Stochastic Oscillator
- NVAX 67.00
- LILAK 96.21
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.